Helena Earl - Concepedia

Author

Helena Earl

University of Cambridge ORCID

Also Known As

Chin, S.-F., D Gareth Evans, D M Ritchie, Earl, H, Earl, Helena, Ferrieres, Jean, H Earl, H J Earl, H M Earl, H. EARL

355

Publications

16.7K

Citations

H-Index

156

Concepts

All Affiliations

University of Cambridge Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust University of Warwick NIHR Cambridge Biomedical Research Centre

About

Helena Earl is an author at University of Cambridge specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	60	5.5K
2	Health Sciences	13	19	944
3	Engineering	8	8	390
4	Arts	1	1	77
5	Education	1	1	38

Helena Earl

128

Publications

11.8K

Citations

H-Index

Page 1

	Year	Citations
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Andrew Tutt, Mark E. Robson, Judy E. Garber, The Lancet Breast OncologyOncologyPathologyPolymerase Inhibitor OlaparibBreast Cancer	2010	1.6K
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients Hager R. Ali, Elena Provenzano, Sarah‐Jane Dawson, Annals of Oncology Breast OncologyCancer ImmunosurveillanceMedicineT-regulatory CellImmunology	2014	763
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society Alexander R. Lyon, Susan Dent, Susannah Stanway, European Journal of Heart Failure	2020	717
Multi-omic machine learning predictor of breast cancer therapy response Stephen‐John Sammut, Mireia Crispin‐Ortuzar, Suet‐Feung Chin, Nature	2021	586
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Richard Gray, Daniel Rea, Kelly Handley, Journal of Clinical Oncology Breast OncologyCancer ManagementEpidemiology Of CancerGynecologyPharmacotherapy	2013	446
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis Roland F. Schwarz, Charlotte K.Y. Ng, Susanna L. Cooke, PLoS Medicine	2015	399
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes H. Raza Ali, Silvia-Elena Glont, Fiona M. Blows, Annals of Oncology Breast OncologyCancer ImmunosurveillanceImmunologyImmune Checkpoint InhibitorBreast Cancer	2015	292
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study Christine Parkinson, Davina Gale, Anna Piskorz, PLoS Medicine	2016	292
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial Helena Earl, Louise Hiller, Anne-Laure Vallier, The Lancet	2019	277
The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel Ahmed A. Ahmed, Anthony D. Mills, Ashraf E.K. Ibrahim, Cancer Cell MedicineGynecologySensitizes Ovarian CancersMatrix BiologyCancer Biology	2007	234

Page 1